Login to the DGSOM Faculty Profiles
Jeremie Calais, M.D., M.Sc.
Affiliations
Affiliations
Member, Physics & Biology in Medicine GPB Home Area
Health Sciences Assistant Clinical Professor, Molecular & Medical Pharmacology
Biography:

Jeremie Calais received his MD degree from the University of Paris-Diderot in 2010. He subsequently trained in nuclear medicine and cancer imaging at the Henri Becquerel Cancer Center of the University of Rouen and was board certified by the French Society of Nuclear Medicine in 2014.

He currently serves as Assistant Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology in the David Geffen School of Medicine at UCLA. His work focuses on improving the outcomes of cancer patients by translating and applying novel diagnostic and therapeutic approaches. He uses PET/CT imaging for cancer phenotyping, radiation therapy planning and therapy response assessment. He leads the clinical theranostics research program at UCLA that combines radionuclide therapy and imaging.

Publications

A selected list of publications:

Calais Jeremie, Czernin Johannes, Cao Minsong, Kishan Amar U, Hegde John V, Shaverdian Narek, Sandler Kiri, Chu Fang-I, King Chris R, Steinberg Michael L, Rauscher Isabel, Schmidt-Hegemann Nina-Sophie, Poeppel Thorsten, Hetkamp Philipp, Ceci Francesco, Herrmann Ken, Fendler Wolfgang P, Eiber Matthias, Nickols Nicholas G   68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning Journal of Nuclear Medicine, 2018; 59(2): 230-237.
Calais Jeremie, Cao Minsong, Nickols Nicholas G   The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer Journal of Nuclear Medicine, 2018; 59(4): 557-567.
Calais Jeremie, Fendler Wolfgang P, Herrmann Ken, Eiber Matthias, Ceci Francesco   Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence Journal of Nuclear Medicine, 2018; 59(5): 789-794.
Calais Jeremie, Fendler Wolfgang P, Eiber Matthias, Gartmann Jeannine, Chu Fang-I, Nickols Nicholas G, Reiter Robert E, Rettig Matthew B, Marks Leonard S, Ahlering Thomas E, Huynh Linda M, Slavik Roger, Gupta Pawan, Quon Andrew, Allen-Auerbach Martin S, Czernin Johannes, Herrmann Ken   Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence Journal of Nuclear Medicine, 2018; 59(3): 434-441.
Calais Jérémie, Kishan Amar U, Cao Minsong, Fendler Wolfgang P, Eiber Matthias, Herrmann Ken, Ceci Francesco, Reiter Robert E, Rettig Matthew B, Hegde John V, Shaverdian Narek, King Christopher R, Steinberg Michael L, Czernin Johannes, Nickols Nicholas G   Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning Journal of Nuclear Medicine, 2018; 59(5): 861.
Calais Jérémie, Dubray Bernard, Nkhali Lamyaa, Thureau Sebastien, Lemarignier Charles, Modzelewski Romain, Gardin Isabelle, Di Fiore Frederic, Michel Pierre, Vera Pierre   High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer European journal of nuclear medicine and molecular imaging, 2015; 42(6): 858-67.
Calais Jérémie, Thureau Sébastien, Dubray Bernard, Modzelewski Romain, Thiberville Luc, Gardin Isabelle, Vera Pierre   Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer Journal of Nuclear Medicine, 2015; 56(2): 196-203.
Chaput Anne, Calais Jérémie, Robin Philippe, Thureau Sébastien, Bourhis David, Modzelewski Romain, Schick Ulrike, Vera Pierre, Salaün Pierre-Yves, Abgral Ronan   Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma Head & neck, 2017; 39(6): 1155-1165.
Calais Jeremie, Czernin Johannes, Eiber Matthias, Fendler Wolfgang P, Gartmann Jeannine, Heaney Anthony P, Hendifar Andrew E, Pisegna Joseph R, Hecht J Randolph, Wolin Edward M, Slavik Roger, Gupta Pawan, Quon Andrew, Schiepers Christiaan, Allen-Auerbach Martin S, Herrmann Ken   Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented Journal of Nuclear Medicine, 2017; 58(11): 1793-1796.
Fendler Wolfgang Peter, Calais Jeremie, Allen-Auerbach Martin, Bluemel Christina, Eberhardt Nina, Emmett Louise, Gupta Pawan, Hartenbach Markus, Hope Thomas A, Okamoto Shozo, Pfob Christian Helmut, Pöppel Thorsten D, Rischpler Christoph, Schwarzenböck Sarah, Stebner Vanessa, Unterrainer Marcus, Zacho Helle D, Maurer Tobias, Gratzke Christian, Crispin Alexander, Czernin Johannes, Herrmann Ken, Eiber Matthias   68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study Journal of Nuclear Medicine, 2017; 58(10): 1617-1623.
Eiber Matthias, Herrmann Ken, Calais Jeremie, Hadaschik Boris, Giesel Frederik L, Hartenbach Markus, Hope Thomas, Reiter Robert, Maurer Tobias, Weber Wolfgang A, Fendler Wolfgang P   Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT Journal of Nuclear Medicine, 2018; 59(3): 469-478.
Eiber Matthias, Fendler Wolfgang P, Rowe Steven P, Calais Jeremie, Hofman Michael S, Maurer Tobias, Schwarzenboeck Sarah M, Kratowchil Clemens, Herrmann Ken, Giesel Frederik L   Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy Journal of Nuclear Medicine, 2017; 58(Suppl 2): 67S-76S.
Lückerath Katharina, Stuparu Andreea D, Wei Liu, Kim Woosuk, Radu Caius G, Mona Christine E, Calais Jeremie, Rettig Matthew, Reiter Robert E, Czernin Johannes, Slavik Roger, Herrmann Ken, Eiber Matthias, Fendler Wolfgang   Detection threshold and reproducibility of 68Ga-PSMA11 PET/CT in a mouse model of prostate cancer Journal of Nuclear Medicine, 2018; 59(5): 861.
Zeitouni Michel, Calais Jérémie, Ghodbane Walid, Ou Phalla, Sannier Aurélie, Bouleti Claire   A Cardiac Myxoma With Intense Metabolic Activity The Canadian journal of cardiology, 2018; 34(1): 92.e11-92.e12.
Calais Jérémie, Pasi Nicoletta, Nguyen Virginia, Hyafil Fabien   Mycotic aneurysm in a pulmonary artery detected with 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging European heart journal, 2017; 38(46): 3474.
Calais Jérémie, Edet-Sanson Agathe, Gaucher Stephane, Vera Pierre, Le Cloirec Joseph   Tc-99m-HMPAO-Labeled Leukocyte SPECT/CT in Pediatrics: Detecting Candida albicans Tricuspid Endocarditis Nuclear medicine and molecular imaging, 2015; 49(4): 333-4.
Calais Jérémie, Lussato David, Menard Jean, De Kerviler Eric, Mongiat-Artus Pierre, Castier Yves, Merlet Pascal   Resection of a solitary pulmonary metastasis from prostatic Adenocarcinoma misdiagnosed as a Bronchocele: usefulness of 18F-choline and 18F-FDG PET/CT Journal of thoracic oncology, 2014; 9(12): 1826-9.
Calais Jérémie, Hapdey Sébastien, Tilly Hervé, Vera Pierre, Chastan Mathieu   Hodgkin's Disease Staging by FDG PET/CT in a Pregnant Woman Nuclear medicine and molecular imaging, 2014; 48(3): 244-6.
Blanc Estelle, Calais Jérémie, Cardot Vincent, Mabille Laurence   (18)F-FDG PET/CT scan in malignant priapism with diffuse pulmonary adenocarcinoma metastatic invasion of both corpus spongiosum and cavernosum European journal of nuclear medicine and molecular imaging, 2014; 41(3): 588-9.
Calais Jeremie, Fendler Wolfgang Peter, Herrmann Ken, Eiber Matthias, Ceci Francesco   Reply: Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way Journal of Nuclear Medicine, 2018; 59(5): 861.
Calais Jérémie, Lussato David, Merlet Pascal   Reply to "18F-Choline PET-CT in the Management of Lung Cancer and Mucinous Tumors?" Journal of thoracic oncology, 2015; 10(6): e49-50.